Media Archive

2018 | 2017 | 2016 | 2015

Press Release

REVOLUTION Medicines Announces Presentations at Scientific Meetings in Third and Fourth Quarters of 2018

Redwood City, CA – November 13, 2018 – REVOLUTION Medicines, Inc. today announced presentations describing scientific research progress across multiple oncology drug discovery programs.

Read more

Press Release

REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets

Redwood City, CA and Cambridge, MA – October 16, 2018 – REVOLUTION Medicines, Inc. and Warp Drive Bio, Inc. announced today that REVOLUTION Medicines is acquiring Warp Drive Bio. The acquisition will combine the companies’ complementary drug…

Read more

Press Release

REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors

Redwood City, CA – October 9, 2018 – REVOLUTION Medicines, Inc. today announced dosing of the first patient in a Phase 1, open-label, monotherapy dose-escalation and expansion study of RMC-4630, the company’s lead investigational drug candidate…

Read more

News

Sanofi looks to Revolution-ize precision oncology in global SHP2 partnership

"We're enjoying the one-two punch," Mark Goldsmith, president and CEO of Revolution Medicines Inc., told BioWorld after the Redwood City, Calif.-based firm inked an oncology partnership with Sanofi SA covering its SHP2 program. In return for an…

Read more

Press Release

Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers

Cambridge, Mass. and Redwood City, CA – July 18, 2018 – Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2,…

Read more

News

Antifungal out, cancer in: Revolution scores $500M Sanofi deal on first oncology program

Less than a year ago, Third Rock startup Revolution Medicines shed its antifungal ambitions and remade itself as an oncology company. Now, the Redwood City-based biotech has apparently wooed Sanofi $SNY into a bang up deal on its first cancer…

Read more

News

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation.

 

Read more

News

Revolution looks to spin into the clinic with $56M series B

Revolution Medicines Inc. (Revmed) strengthened its balance sheet with a $56 million series B while bolstering its C-suite with a trio of executives. The financing will enable the company to advance its lead SHP2 program through IND and into what…

Read more

News

Revolution Medicines tees up for oncology IND with $56M series B

Revolution Medicines started out in 2014, with a platform that breaks down natural compounds into their composite parts and reassembles them into usable drugs. The company has since zeroed in on oncology and now, with a $56 million round in the…

Read more

Press Release

REVOLUTION Medicines Raises $56 Million in Series B Financing

Redwood City, CA – April 24, 2018 – REVOLUTION Medicines, Inc., a drug discovery and development company focused on frontier cancer targets, today announced it has raised $56 million in a Series B financing to support its ongoing R&D programs…

Read more

Publication / Presentation

Press Release

Revolution Medicines Appoints Vincent Miller, M.D. to Board of Directors

Redwood City, CA –October 5, 2017 – REVOLUTION Medicines, Inc., a drug discovery and development company focused on frontier cancer targets, today announced the appointment of Vincent Miller, M.D., to its board of directors. Dr. Miller is a…

Read more

Press Release

Revolution Medicines Reports Discovery that May Expand Range of Clinically Actionable Cancer Mutations

Redwood City, CA –September 14, 2017 – REVOLUTION Medicines, Inc., a company focused on frontier cancer targets and drug discovery, today published a report entitled “Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling…

Read more

Publication / Presentation

Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss

New research revealed an unexpected dependence of some cancer-causing forms of proteins in the RAS-MAP kinase pathway on the normal biochemical actions of SHP2.  These functions can be disrupted by small molecule inhibitors of SHP2 designed by…

Read more

Press Release

Revolution Medicines Appoints Cancer Leader Dr. Stephen Kelsey as President of Research and Development

Redwood City, CA –March 20, 2017 – REVOLUTION Medicines, Inc., a company focused on frontier cancer targets and drug discovery inspired by nature’s lessons, today announced the appointment of Stephen (Steve) Kelsey, M.D., an…

Read more

Press Release

Revolution Medicines Raises Additional $25 Million in Series A Financing

Redwood City, Calif. – December 20, 2016 – REVOLUTION Medicines, Inc., a company focused on frontier cancer targets and drug discovery inspired by nature’s lessons, today announced that it has raised $25 million in a Series A extension financing…

Read more

Press Release

Revolution Medicines Names Distinguished Cancer Scientists and Drug Hunters to Senior Advisory Roles

Redwood City, CA – December 13, 2016 – REVOLUTION Medicines, Inc., a company focused on frontier cancer targets and drug discovery inspired by nature’s lessons, today announced that noted chemical biologist and cancer…

Read more

Press Release

Revolution Medicines Names Academic Co-Founder, Michael Fischbach, Ph.D., and Senior Advisor, Eric Gordon, Ph.D.

Redwood City, CA – June 14, 2016 – REVOLUTION Medicines, Inc., a company focused on the discovery and development of innovative drugs inspired by natural products, today announced that noted chemical biologist…

Read more

News

Cover Story: 10 Start-Ups To Watch - Revolution Medicines

Mother Nature is a master chemist. More than half of the pharmacopoeia starts with a compound generated by her hands. But there’s a catch: The complexity of natural products can make them tough—sometimes impossible—to re-create in a lab, let…

Read more

News

Revolution Medicines - 2015 Fierce 15

The scoop: As drug discovery platforms go, none is older than evolution. Over billions of years, the slow march of life has brought about natural agents gradually selected for their ability to modulate certain biological…

Read more

Press Release

FierceBiotech Names Revolution Medicines as a “Fierce 15” Biotech Company of 2015

Redwood City, CA – September 30, 2015 – REVOLUTION Medicines, Inc., a company focused on the discovery and development of innovative drugs derived from natural compounds, today announced that it has been named by FierceBiotech as…

Read more

Press Release

Rationally Designed Antifungal Compounds that Evade Resistance Reported in Nature Chemical Biology by Scientific Founder of Revolution Medicines

Redwood City, Calif., June 1, 2015 – REVOLUTION Medicines, Inc., a company focused on the discovery and development of innovative drugs derived from natural compounds, announced that progress in antimicrobial drug discovery was…

Read more

Press Release

Revolution Medicines Appoints Pharmaceutical Commercial Executive Elizabeth McKee Anderson to Board of Directors

San Francisco/Redwood City, Calif., April 9, 2015 – REVOLUTION Medicines, Inc., a company focused on the discovery and development of innovative drugs derived by redesigning natural compounds, today announced the…

Read more

Press Release

Major Advances in Synthetic Chemistry Reported in Science by Founding Scientist of Revolution Medicines

Redwood City, Calif., March 12, 2015 – REVOLUTION Medicines, Inc., a company focused on the discovery and development of innovative drugs derived from natural compounds, today announced the publication of new research by the…

Read more

Press Release

Revolution Medicines Expands Executive Leadership Team

San Francisco/Redwood City, Calif., March 5, 2015 – REVOLUTION Medicines, Inc., a company focused on the discovery and development of innovative drugs derived from natural compounds, today announced the appointment of two senior…

Read more

Press Release

Third Rock Ventures Launches Revolution Medicines with $45 Million Series A to Redesign Evolution’s Products to Treat Serious Diseases

San Francisco/Redwood City, Calif. – February 4, 2015 – Third Rock Ventures, LLC today announced the formation of REVOLUTION Medicines, Inc. with a $45 million Series A financing to…

Read more